Investment Rating
-
Master Rating:
-
Amerise Biosciences has an operating revenue of Rs. 10.56 Cr. on a trailing 12-month basis. An annual revenue growth of 5735% is outstanding, Pre-tax margin of 6% is okay, ROE of 9% is fair but needs improvement. From an O'Neil Methodology perspective, the stock has an EPS Rank of 29 which is a POOR score indicating inconsistency in earnings, a RS Rating of 6 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at E which indicates heavy supply, Group Rank of 143 indicates it belongs to a poor industry group of Finance-Blank Check and a Master Score of D is close to being the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment. Please note that this is a thinly traded stock.
EPS Strength
Price Strength
Buyer Demand
Group Rank
Result Highlights
Synopsis
BSE-Finance-Blank Check
Amerise Biosciences belongs to the Industry of Pharmaceuticals. Company’s Total Operating Revenue is Rs. 0.00 Cr. and Equity Capital is Rs. 6.61 Cr. for the Year ended 31/03/2021. Amerise Biosciences Ltd. is a Public Limited Listed company incorporated on 27/08/1984 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L29199GJ1984PLC007195 and registration number is 007195.- Market Cap
- 6
- Sales
- 8
- Shares in Float
- 6.61
- No of funds
- Yield
- Book Value
- 1.13
- U/D Vol ratio
- 0.8
- LTDebt / Equity
- 1
- Alpha
- -0.18
- Beta
- 0.28
- Owner Name
- Jun-22
- Mar-22
- Dec-21
- Sep-21
- Individual Investors
- 72.28%
- 57.53%
- 13.01%
- Others
- 27.72%
- 42.47%
- 86.99%
Management
- Name
- Designation
- Ms. Manisha Maneklal Patel
- Director
- Mr. Dineshkumar Tribhovanbhai Rathod
- WholeTime Director & CFO
- Mr. Niraj Vaghela
- Director
Forecast
Price Estimates
FAQs
What is Share Price of ?
share price is ₹ As on 09 August, 2022 | 18:24